Please assess the completion status of the following clinical trial:

Trial Title: Teduglutide for Enterocutaneous Fistula (ECF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18~* Enterocutaneous fistula (ECF) that could be secondary to volvulus, injury, prior trauma or surgery, or vascular ischemia~Exclusion Criteria:~* Perianal fistula~* Clinical suspicion of inflammatory bowel disease~* History of radiation enteritis or sprue (as defined by history)~* Active (\<1 year) alcohol or drug abuse~* Significant hepatic, or cardiac diseases as defined as:~* Hepatic: aspartate aminotransferase (AST) \> 2 times upper limit of normal (10-40 U/L)~* Cardiac: unstable angina or evidence of active myocardial ischemia (elevated troponin level drawn by clinical suspicion)~* Severe renal dysfunction: serum creatinine \> 2 times upper limit of normal (0.6-1.5 mg/dL)~* Received glutamine less than 4 weeks prior to screening~* Receiving growth factors (erythropoietin, granulocyte colony-stimulating factor, granulo-cyte-macrophage colony stimulating factor, and human growth hormone)~* Pregnancy or lactation (women of childbearing age will be excluded if they do not agree to either complete sexual abstinence during the study or if they refuse to use at least two forms of highly effective contraception such as oral contraception, injectable or implantable contraception, vaginal rings, or intrauterine devices (IUD))~* Active malignancy or suspicion for gastrointestinal malignancy on CT scan~* Not capable of understanding or not willing to adhere to the study visit schedule and drug administration requirements~* Family history of intestinal malignancy (gastric, small intestine, colon)~* Personal or family history of hereditary non-polyposis colorectal cancer, familial adenomatous polyposis, first degree relative with colon cancer~* Positive hemoccult (per rectum)~* Abnormal baseline electrocardiogram (ECF) suggestive of congestive heart failure or underlying cardiac disease~* Taking oral benzodiazepines, barbiturates, or phenothiazines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care followed by Teduglutide (Type: EXPERIMENTAL): Participants in this group will receive standard of care treatment for the first 8 weeks followed by daily Teduglutide for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure.
- Teduglutide followed by Standard of Care (Type: EXPERIMENTAL): Participants in this group will receive daily Teduglutide treatment for the first 8 weeks followed by standard of care for the next 8 weeks.~Subjects with a favorable response will be offered an open label extension during which they will continue to receive teduglutide for up to another 12 months or permanent fistula closure

Based on this trial design, predict the completion outcome and termination type (if applicable).